• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Nanobiotix (ENXTPA:NANO) Gains Fresh Attention After Melanoma Data But Is The Value Case Priced In

    Simply Wall St·10/28/2026 08:12:50
    Listen to the news

    Nanobiotix (ENXTPA:NANO) is back in focus after updated Phase 1 data for JNJ-1900 in anti-PD-1-resistant advanced primary cutaneous melanoma highlighted acceptable safety and early efficacy signals in a difficult-to-treat population.

    The latest melanoma update lands against a backdrop of sharp moves in Nanobiotix shares, with a 7.37% 1-day and 42.92% 7-day share price return at a €30.3 close, while the 90-day share price return declined 8.07% and the 1-year total shareholder return reached 95.74%, indicating strong longer-term momentum despite recent volatility.

    Spot 123 healthcare AI stocks that, like Nanobiotix, are trying to turn complex oncology science into potential catalysts for share price re-rating.

    The question now is simple. After Nanobiotix’s sharp move and mixed recent returns, does it make more sense to pay up today or wait for a calmer entry as the valuation case is tested next?

    Most Popular Narrative: 42% Undervalued

    Against a last close of €30.3, the most followed Nanobiotix narrative anchors fair value at €52.2. This frames the latest rally as only part of the repricing story rather than the end of it.

    The collaboration with Johnson & Johnson on NBTXR3, including a large Phase III in head and neck cancer and the CONVERGE Phase II in lung cancer, concentrates development on indications that management describes as sizable markets, which could influence future product revenue and milestone inflows if these programs progress.

    See why 5 investors see Nanobiotix as 42% undervalued.

    Result: Fair Value of €52.2 (UNDERVALUED)

    Still, Nanobiotix’s story could shift quickly if the NANORAY 312 or CONVERGE trials miss key endpoints, or if Curadigm partnerships fail to materialise.

    Find out about the key risks to this Nanobiotix narrative.

    Next Steps

    If this mix of enthusiasm and concern around Nanobiotix leaves you undecided, move quickly to inspect the numbers and context yourself. Then weigh the 2 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Nanobiotix?

    Do not stop with Nanobiotix. Use the Simply Wall Street screener to compare different angles, pressure test your thinking, and spot opportunities you might otherwise overlook.